Clara Rodríguez Fernández, Author at Labiotech.eu - Page 7 of 62

About

Traveler, musician, food enthusiast and book worm. Always on the hunt for interesting facts and news.

Articles by Clara Rodríguez Fernández

Spain biotech ecosystem Ysios Capital

Interview 5 Jun 2019

How Spain is Building a Strong Biotech Ecosystem

The biotech sector is rapidly gaining momentum in Spain. At Labiotech Refresh in Barcelona, Raúl Martín-Ruiz, Partner at the venture capital firm Ysios Capital, shared his experience investing in Spain’s biotech industry over the last decade. Ysios Capital made its first investment in 2008. The recipient was a cell therapy company based in Madrid. Then […]

June 5, 2019 - 4 minutesmins - By Clara Rodríguez Fernández

CRISPR babies death risk

News and Trends 3 Jun 2019

‘CRISPR Babies’ Might Be at Risk of Dying Younger

Update (01/10/2019): The scientists behind the study have declared that the results were based on erroneous data, meaning the mutation they studied has a weaker effect on mortality than initially reported. A new study highlights the issues that can result from modifying human DNA without sufficient understanding of how it can impact our health. Last […]

June 3, 2019 - 3 minutesmins - By Clara Rodríguez Fernández

Agrosustain crop mold pesticide

Interview 30 May 2019

Taking Inspiration from Plants to Prevent Mold from Ruining Crops

Olga Dubey founded the Swiss startup Agrosustain with the intention to bring forth a natural alternative to chemical pesticides against mold. She shares how it all started and her company’s plans to end the massive amounts of food waste that mold is responsible for. “Mold is everywhere, so it’s something that is very hard to […]

May 30, 2019 - 4 minutesmins - By Clara Rodríguez Fernández

Filippo Petti Celyad

Interview 28 May 2019

Getting Ahead of the Pack in the CAR-T Field

Celyad is one of many companies in the immuno-oncology field seeking to take the lead in the development of a new generation of CAR-T cell therapy that outperforms its predecessors Yescarta and Kymriah in both efficacy and safety. Filippo Petti, CEO of Celyad, shares the company’s strategy to get ahead in such a crowded field. […]

May 28, 2019 - 6 minutesmins - By Clara Rodríguez Fernández

Fountain Healthcare Partners

More News! 23 May 2019

Irish Life Sciences VC Raises €118M Fund with European Focus

Fountain Healthcare Partners has raised €118M in its third fund dedicated to investing in life sciences, with the majority of the funds destined to go to European companies. Of the total raised, €45M was contributed by the European Investment Fund, which invested in both of Fountain’s previous funds. Other investors are Coolidge Limited, the Ireland […]

May 23, 2019 - 2 minutesmins - By Clara Rodríguez Fernández

Molecular Partners drug development cancer

Interview 16 May 2019

Taking a Drug to Market “Is a Marathon, Not a Sprint”

Based in Zurich, Molecular Partners is developing a new class of drugs that can address the complexity of cancer. At Labiotech Refresh in Zurich, CEO Patrick Amstutz shared what he’s learned on the journey to take the company where it is today. After completing a PhD at ETH Zurich, Amstutz founded Molecular Partners with a […]

May 16, 2019 - 4 minutesmins - By Clara Rodríguez Fernández

ADVERTISEMENT

human microbiome research

In Depth 15 May 2019

The Missing Piece in the Microbiome Field

Over the last decade, the biotech industry has built a lot of hype around the emerging field of microbiome research. Its potential to treat all sorts of diseases has captured the imagination of scientists and the number of early-stage studies is growing massively day by day. These studies have found correlation between the human microbiome […]

May 15, 2019 - 7 minutesmins - By Clara Rodríguez Fernández

Peptomyc myc cancer drug

Interview 9 May 2019

A 20-Year Journey to Nail Down an Undruggable Cancer Target

The ultimate goal of cancer research is to bring to the market a drug that improves the treatment of patients lacking options. Laura Soucek, CEO of the startup Peptomyc, shares the story of her journey to take a cancer treatment against an until now undruggable target to the clinic. It all started when Soucek was […]

May 9, 2019 - 5 minutesmins - By Clara Rodríguez Fernández

Confo Therapeutics GPCR

News and Trends 7 May 2019

Belgian Biotech Raises €30M Series A to Unlock Undruggable Targets

Confo Therapeutics has raised €30M in a Series A round that will take its unique technology to find drugs for historically undruggable targets to clinical trials. The fundraising was led by the VCs BioGeneration Ventures and Wellington Partners, and joined by several other private and public investors. With the money, Confo Therapeutics aims to […]

May 7, 2019 - 3 minutesmins - By Clara Rodríguez Fernández

Cell Medica CAR NKT cell therapy

News and Trends 1 May 2019

Next-Generation CAR-T Therapy Shows Promise in Child’s Neuroblastoma

Cell Medica’s next-generation CAR-T cell therapy has resulted in ‘extensive tumor regression’ in a child with high-risk neuroblastoma, one of the deadliest types of childhood cancer. Only available to cancer patients for the last couple of years, CAR-T cell therapy has had impressive results in treating patients for whom other available options do […]

May 1, 2019 - 3 minutesmins - By Clara Rodríguez Fernández

Early stage biotech funding

Interview 1 May 2019

What’s Driving the Boom in Early Stage Biotech Funding?

The biotech industry is seeing a massive increase in the amount of funding available to early-stage research. At Bio Europe Spring, we spoke to Nerida Scott, VP of New Ventures and Transactions at Johnson & Johnson Innovation, to learn more about what’s behind it. In the last five years, the total invested in seed and […]

May 1, 2019 - 4 minutesmins - By Clara Rodríguez Fernández

Givaudan AMSilk spider silk cosmetics

News and Trends 30 Apr 2019

Cosmetics Giant Acquires German Biotech’s Spider Silk Cosmetics Arm

The Swiss Givaudan, one of the largest cosmetics, flavors and fragrances companies in the world, has acquired the cosmetics business of AMSilk, a biotech company that uses genetic engineering to produce spider silk proteins in bacteria. Silk is a valuable material in the cosmetics industry, used to offer protection against pollution and keep cosmetic […]

April 30, 2019 - 3 minutesmins - By Clara Rodríguez Fernández

ADVERTISEMENT